SAKURA 1 study meets primary endpoint for treatment of noninfectious uveitis

LONDON — A study of intravitreal sirolimus for the treatment of noninfectious uveitis has achieved its primary endpoint, a speaker said here, reporting the data for the first time worldwide.At the Euretina Congress, Quan Dong Nguyen, MD, MSc, said a proportion of patients in the phase 3, multicenter, randomized, double-masked SAKURA 1 study had achieved a vitreous haze (VH) score of 0 at month 5 — the study’s primary endpoint — as well as the key secondary endpoint of a VH score of 0.5+ at month 5.